Lin BioScience, Inc. (TPEX:6696)

Lin BioScience Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-1,363	-744.27	-687.19	-313.52	-434.7
Depreciation & Amortization	23.79	20.05	17.93	11.16	4.39
Other Amortization	-	0.16	-	-	-
Loss (Gain) From Sale of Assets	-	-	-	-	-0.22
Loss (Gain) From Sale of Investments	-	-1.57	-	-	-
Stock-Based Compensation	1,204	291.06	115.15	44.39	8.91
Other Operating Activities	-1,417	-638.24	-378.32	-105.16	105.77
Change in Accounts Receivable	-1.96	25.07	-25.02	1.46	-1.48
Change in Accounts Payable	127.53	8.36	60.64	13.32	19.46
Change in Other Net Operating Assets	-14.79	20.08	-116.02	-12.66	8.02
Operating Cash Flow	-1,441	-1,019	-1,013	-361.01	-289.84
Capital Expenditures	-7.2	-5.82	-1.97	-22.38	-2.12
Sale of Property, Plant & Equipment	-	-	-	-	0.51
Sale (Purchase) of Intangibles	-0.97	-1.53	-	-	-
Investment in Securities	-9,534	-3,612	-	-	-
Other Investing Activities	178.1	68.2	3.83	-1.67	0.13
Investing Cash Flow	-9,364	-3,551	1.87	-24.06	-1.48
Long-Term Debt Repaid	-16.42	-14.63	-11.86	-5.53	-2.91
Net Debt Issued (Repaid)	-16.42	-14.63	-11.86	-5.53	-2.91
Issuance of Common Stock	755.59	98.38	622.41	511	31.23
Other Financing Activities	19,742	2,581	2,026	624.32	-
Financing Cash Flow	20,481	2,665	2,637	1,130	28.32
Foreign Exchange Rate Adjustments	744.13	132.64	-10.14	93.66	-22.41
Net Cash Flow	10,420	-1,773	1,616	838.39	-285.4
Free Cash Flow	-1,449	-1,025	-1,015	-383.4	-291.96
Free Cash Flow Per Share	-17.64	-13.04	-13.72	-5.34	-4.24
Cash Interest Paid	-	1	1.21	0.88	0.07
Cash Income Tax Paid	-	-69.4	-29.53	-18.4	-9.53
Levered Free Cash Flow	-1,662	-573.21	-635.88	-658.48	-31.55
Unlevered Free Cash Flow	-1,661	-572.58	-635.13	-657.93	-31.5
Change in Working Capital	110.78	53.51	-80.39	2.12	26.01

Source: S&P Global Market Intelligence. Standard template. Financial Sources.